Disease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD Experts) Delphi panel.

Autor:	Trzeciak M; Department of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland., Rudnicka L; Department of Dermatology, Medical University of Warsaw, Warsaw, Poland., Arenberger P; Department of Dermatovenerology, Third Faculty of Medicine, Charles University of Prague, Prague, Czechia., Engin B; Department of Dermatology and Venerology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, İstanbul, Türkiye., L'vov A; Department of Dermatology, Federal State Budgetary Institution of Continuing Professional Education 'Central State Medical Academy', Moscow, Russia.; Department of Dermatology, Medical Research and Educational Center, Lomonosov Moscow State University, Moscow, Russia., Alper S; Department of Dermatology and Venereology, Koç University, İstanbul, Türkiye., Alpsoy E; Department of Dermatology and Venereology, Akdeniz University, Antalya, Türkiye., Benáková N; Department of Dermatovenereology, 1st Medical Faculty, Charles University, Prague, Czechia., Bobko S; Moscow Scientific and Practical Centre of Dermatovenereology and Cosmetology, Moscow, Russia., Borlu M; Department of Dermatology and Venereology, Erciyes University, Kayseri, Türkiye., Czarnecka-Operacz M; Department of Dermatology, Medical University of Poznań, Poznań, Poland., Elisyutina O; NRC Institute of Immunology FMBA of Russia, Moscow, Russia., Ergun T; Department of Dermatology, Marmara University, İstanbul, Türkiye., Ertam I; Department of Dermatology, Ege University, İzmir, Türkiye., Fedenko E; NRC Institute of Immunology FMBA of Russia, Moscow, Russia., Filipovská O; Department of Dermatology, Hospital in Ústí nad Labem, Ústí nad Labem, Czechia., Fomina D; Centre of Allergy and Immunology, Clinical State Hospital 52, Moscow Ministry of Healthcare, Moscow, Russia.; Department of Dermatology, I. M. Sechenov Moscow Medical University, Moscow, Russia., Gadzhigoroeva A; Moscow Scientific and Practical Centre of Dermatovenereology and Cosmetology, Moscow, Russia., Kojanová M; Department of Dermatovenereology, 1st Medical Faculty, Charles University, Prague, Czechia., Lesiak A; Dermatology and Venereology Clinic, Medical University, Łodź, Poland., Michenko A; Department of Dermatology, Federal State Budgetary Institution of Continuing Professional Education 'Central State Medical Academy', Moscow, Russia.; Department of Dermatology, Medical Research and Educational Center, Lomonosov Moscow State University, Moscow, Russia., Murashkin N; Department of Dermatology, Federal State Autonomous Institution, Scientific Centre of Children's Health of the Ministry of Health of the Russian Federation, Moscow, Russia., Owczarek W; Department of Dermatology, Military Institute of Medicine, Warsaw, Poland., Özkaya E; Istanbul Faculty of Medicine, Department of Dermatology and Venereology, Istanbul University, İstanbul, Türkiye., Plzáková Z; Department of Dermatovenereology, 1st Medical Faculty, Charles University, Prague, Czechia., Reich A; Department of Dermatology, University of Rzeszow, Rzeszów, Poland., Selerova M; Department of Dermatology, AGEL, Prague, Czechia., Gurbuz BA; Pfizer, İstanbul, Türkiye.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2024 Jun 19; Vol. 11, pp. 1402493. Date of Electronic Publication: 2024 Jun 19 (Print Publication: 2024).
DOI:	10.3389/fmed.2024.1402493
Abstrakt:	Background: There is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get information-driven insights regarding the current disease burden and clinical management of patients with moderate-to-severe AD with common and differentiating aspects of the patient journey and establish a consensus. Methods: In this modified 2-round Delphi panel, 133 questions were asked in total to 27 dermatologists. A consensus was achieved when 70% of the panel members strongly agreed or agreed (or strongly disagreed or disagreed) with an item. Statements with <40% agreement dropped from the Delphi rounds and were not repeated. Results: The results state that AD has a significant impact on the quality of life for both patients and their families with social and economic consequences in these countries. While there were significant dissimilarities regarding the current treatment approach by preference order and treatment duration among participants, there was also a high percentage of consensus on literature and guideline-based statements. Current topical therapies and the immune response modifiers were not found to be sufficient by panelists to cover the therapeutic needs of patients with moderate-to-severe AD. Moreover, panelists highlighted the significant burden of adverse events with the off-label use of currently available immunosuppressants. Conclusions: These results underlined that there is a significant disease burden with an unmet treatment need for patients with moderate-to-severe AD in Poland, Czechia, Russia, and Turkiye. Competing Interests: All panel members/authors received honoraria from Pfizer for their consultancy on answering the questionnaires. DF has acted in advisory board of Novartis, Takeda, GlaxoSmithKline and has received speaker honorarium from Abbvie, Novartis, GlaxoSmithKline, Sanofi, Takeda, CSl Behring, AstraZeneca. MS has acted in advisory board of Novartis, Pfizer, Bristol Byers Squibb and has received speaker honorarium from Abbvie and Pfizer. AL'v has acted in advisory board of Bayer AG, Pfizer, Novartis, Abbvie, and Sanofi and has received speaker honorarium from Pfizer, LEO Pharma, Sanofi, Janssen, Bayer AG, and Sun Pharma. MT has acted in advisory board of Sanofi, Abbvie, and Leopharma, has received speaker honorarium from Abbvie, Bioderma, LEO Pharma, Pierre Fabre, La Roche Possey, Bausch Health, Mead Johnson, Eli Lilly and subinvestigator in clinical trials sponsored by Amge, Novartyis, and Pfizer. MB has acted in advisory board of UCB, Sanofi, Novartis, Pfizer, Lilly, Janssen, Abbvie, and has received speaker honorarium from UCB, Sanofi, Novartis, Pfizer, Lilly, Janssen, and Abbvie. AM has acted in advisory board of Bayer AG and has received honorarium from L'Oreal, Roche, and Novartis. ZP has acted in advisory board of Novartis, Pfizer, and Bristol Byers Squibb and has received speaker honorarium from Pfizer and Abbvie. EA has acted in advisory board of Novartis, Johnson and Johnson, and Abbvie and has received speaker honorarium from Novartis, Johnson and Johnson, and Abbvie. AR has been a consultant or speaker for AbbVie, Bioderma, Bristol-Myers Squibb, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre-Fabre, Sandoz, and Trevi; and principal investigator or sub investigator in clinical trials sponsored by Abbvie, Argenx, Corbus, Drug Delivery Solutions Ltd., Eli Lilly, Galderma, Genentech, Janssen, Kymab Limited, LEO Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, Trevi, and VielaBio. OE has acted in advisory boards of Abbvie, Eli-Lilly, Pfizer, and Sanofi and has received speaker honorarium from Abbvie, Sanofi, Berlin-Chemie/Menarini, and Eli-Lilly. EÖ has acted in advisory boards of Pfizer and Sanofi, and has received speaker honorarium from Pfizer and Sanofi. MK has served as consultant, speaker, or investigator for Abbvie, Amgen, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, and UCB. BE has acted in advisory board of Novartis, Lilly, and Abbvie and has received speaker honorarium from Novartis and Abbvie. EF has acted in advisory board of Novartis, Pfizer, Abbvie, Sanofi, and Eli Lilly and has received speaker honorarium from Novartis, Pfizer, Abbvie, Sanofi, Eli Lilly, and Berlin-Chemie/Menarini. WO has worked as a Consultant or Speaker and participated as Principal Investigator or Subinvestigator in clinical trials sponsored by AbbVie, Alfasigma, Almirall, Bioderma, Bristol-Myers Squibb, Egis, Eli Lilly, Galenica, Galderma, Janssen-Cilag, Leo Pharma, Medac GmbH, Mylan, Novartis, Pfizer, Pierre-Fabre, Roche, Sandoz, Teva Pharmaceuticals, and UCB Pharma. MC-O has acted in the Advisory Board of Novartis and Pfizer. OF has acted in advisory board of Lilly, Novartis, Abbvie, Sanofi, and Janssen and was Principal Investigator in clinical studies of Bristol Myers Squibb, Pfizer, Abbvie, Sanofi, Lilly, Novartis, and Janssen. NM has received research grants from Jansen, Eli Lilly, and Novartis; has acted in advisory board of Galderma, Pierre Fabre, Bayer, LEO Pharma, Pfizer, AbbVie, Amryt Pharma, Zeldis Pharma LLC companies and has received speaker honorarium from LEO Pharma, Abbvie, Novartis, and Viatris. AG has received speaker honorarium from Pfizer, L'Oreal, and Piere Fabre. SB has received speaker honoraria/travel fees from LEO Pharma. ALe has acted in advisory board of Novartis, Abbvie, Leo pharma, Sandoz, Sanofi, and Jansssen Squibb and has received speaker honorarium from Pfizer, Abbvie, Sandoz, Novartis, Leo pharma, Galderma, and Janssen. LR member of advisory boards –Janssen Pharmaceutical Companies, L'Oreal, Leo Pharma, Lilly, Pfizer, Sanofi, Novartis, UCB; invited speaker – Eli Lilly, Leo Pharma, Abbvie, L'Oreal, Lilly, and Pierre Fabre. SA has acted in advisory board of Novartis, Pfizer Pharmaceuticals, and Bristol Myers Squibb and has received speaker honorarium from Pfizer and Abbvie. BG is an employee of Pfizer. (Copyright © 2024 Trzeciak, Rudnicka, Arenberger, Engin, L'vov, Alper, Alpsoy, Benáková, Bobko, Borlu, Czarnecka-Operacz, Elisyutina, Ergun, Ertam, Fedenko, Filipovská, Fomina, Gadzhigoroeva, Kojanová, Lesiak, Michenko, Murashkin, Owczarek, Özkaya, Plzáková, Reich, Selerova and Gurbuz.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu